HUTCHMED (00013) to Present Latest Data from Multiple Proprietary Compound Studies at 2025 World Conference on Lung Cancer and CSCO 2025 Annual Conference

Stock News

2025/09/05

HUTCHMED (00013) announced that it will present the latest and updated data from multiple studies of its proprietary compounds at the 2025 World Conference on Lung Cancer (WCLC) to be held September 6-9, 2025 in Barcelona, Spain, and at the Chinese Society of Clinical Oncology (CSCO) 2025 Annual Conference to be held September 10-14, 2025 in Jinan, China.

According to the announcement, the latest analytical results from the SACHI study, SAVANNAH study, and a Phase IIIb confirmatory study of savolitinib for the treatment of non-small cell lung cancer will be presented at the 2025 World Conference on Lung Cancer. Savolitinib is a potent, highly selective oral MET tyrosine kinase inhibitor (TKI) co-developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.

Data from the first-in-human Phase I clinical trial of HMPL-653 (a novel, selective, potent CSF-1R inhibitor) in Chinese patients with tenosynovial giant cell tumor will be presented for the first time at the 2025 CSCO Annual Conference.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1118480758"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1118480758\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1118480758?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-05 08:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118480758","market":"other","top_or_hot":-1,"title":"HUTCHMED (00013) to Present Latest Data from Multiple Proprietary Compound Studies at 2025 World Conference on Lung Cancer and CSCO 2025 Annual Conference","media":"Stock News","content":"<p>HUTCHMED (00013) announced that it will present the latest and updated data from multiple studies of its proprietary compounds at the 2025 World Conference on Lung Cancer (WCLC) to be held September 6-9, 2025 in Barcelona, Spain, and at the Chinese Society of Clinical Oncology (CSCO) 2025 Annual Conference to be held September 10-14, 2025 in Jinan, China.</p>\n<p>According to the announcement, the latest analytical results from the SACHI study, SAVANNAH study, and a Phase IIIb confirmatory study of savolitinib for the treatment of non-small cell lung cancer will be presented at the 2025 World Conference on Lung Cancer. Savolitinib is a potent, highly selective oral MET tyrosine kinase inhibitor (TKI) co-developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.</p>\n<p>Data from the first-in-human Phase I clinical trial of HMPL-653 (a novel, selective, potent CSF-1R inhibitor) in Chinese patients with tenosynovial giant cell tumor will be presented for the first time at the 2025 CSCO Annual Conference.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUTCHMED (00013) to Present Latest Data from Multiple Proprietary Compound Studies at 2025 World Conference on Lung Cancer and CSCO 2025 Annual Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED (00013) to Present Latest Data from Multiple Proprietary Compound Studies at 2025 World Conference on Lung Cancer and CSCO 2025 Annual Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-05 08:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HUTCHMED (00013) announced that it will present the latest and updated data from multiple studies of its proprietary compounds at the 2025 World Conference on Lung Cancer (WCLC) to be held September 6-9, 2025 in Barcelona, Spain, and at the Chinese Society of Clinical Oncology (CSCO) 2025 Annual Conference to be held September 10-14, 2025 in Jinan, China.</p>\n<p>According to the announcement, the latest analytical results from the SACHI study, SAVANNAH study, and a Phase IIIb confirmatory study of savolitinib for the treatment of non-small cell lung cancer will be presented at the 2025 World Conference on Lung Cancer. Savolitinib is a potent, highly selective oral MET tyrosine kinase inhibitor (TKI) co-developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.</p>\n<p>Data from the first-in-human Phase I clinical trial of HMPL-653 (a novel, selective, potent CSF-1R inhibitor) in Chinese patients with tenosynovial giant cell tumor will be presented for the first time at the 2025 CSCO Annual Conference.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1118480758","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118480758","pubTimestamp":1757030911,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HUTCHMED (00013) announced that it will present the latest and updated data from multiple studies of its proprietary compounds at the 2025 World Conference on Lung Cancer (WCLC) to be held September...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1588":"回港中概股","00013":"和黄医药","BK4007":"制药","BK4531":"中概回港概念","BK4588":"碎股","HCM":"和黄医药","BK4585":"ETF&股票定投概念","BK1587":"次新股"},"translate_title":"和黄医药(00013)将于2025年世界肺癌大会暨CSCO 2025年年会展示多项专利化合物研究最新数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1,"HCM":1},"content_text":"HUTCHMED (00013) announced that it will present the latest and updated data from multiple studies of its proprietary compounds at the 2025 World Conference on Lung Cancer (WCLC) to be held September 6-9, 2025 in Barcelona, Spain, and at the Chinese Society of Clinical Oncology (CSCO) 2025 Annual Conference to be held September 10-14, 2025 in Jinan, China.\nAccording to the announcement, the latest analytical results from the SACHI study, SAVANNAH study, and a Phase IIIb confirmatory study of savolitinib for the treatment of non-small cell lung cancer will be presented at the 2025 World Conference on Lung Cancer. Savolitinib is a potent, highly selective oral MET tyrosine kinase inhibitor (TKI) co-developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.\nData from the first-in-human Phase I clinical trial of HMPL-653 (a novel, selective, potent CSF-1R inhibitor) in Chinese patients with tenosynovial giant cell tumor will be presented for the first time at the 2025 CSCO Annual Conference.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}